There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/12/2025
Locations: Research Site, Houston, Texas
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: Baylor College of Medicine Medical Center- Site Number : 8401170, Houston, Texas
Conditions: Multiple Sclerosis
Register for Updates
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
NCT03425526
Recruiting
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Register for Updates
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
NCT05879146
Recruiting
To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Tumor
Register for Updates
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT05648500
Recruiting
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to severe symptoms. The main questions it aims to answer are: * How well cenerimod works on top of the treatment already being administered. * How safe cenerimod is for adult patients with Systemic Lupus Erythematosus. Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already be... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Houston MD Medspa and Wellness Clinic, Houston, Texas +1 locations
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
NCT05840484
Recruiting
Prostate cancer is the most commonly diagnosed cancer in men. However, there is a wide range in prognosis determined by a host of factors. This study will evaluate the feasibility of guiding therapeutic intervention electronically facilitated symptom and disease monitoring in patients being followed on Active Surveillance. Additionally, we will develop a tissue and data resource to support discovery and hypothesis generation to evaluate germline and/or somatic alterations in relation to cancer-s... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689
Recruiting
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Register for Updates
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037
Recruiting
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Baylor College of Medicine- Site Number : 8400024, Houston, Texas +1 locations
Conditions: Lung Transplant Rejection
Register for Updates
Minimally-invasive Stabilization of Pelvic Metastases With Photodynamic Nails: A Multi-center Prospective Study of Functional Outcome
NCT06083896
Recruiting
Determine whether patients exhibit early functional improvement after minimally-invasive placement of Illuminoss photodynamic nails for peri-acetabular pelvic metastasis at 3 months following procedure
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Pelvic Metastasis
Register for Updates
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
NCT06018428
Recruiting
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/12/2025
Locations: Houston, Texas, Houston, Texas
Conditions: Alopecia Areata
Register for Updates
Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
NCT05928325
Recruiting
This trial studies the effect of a geriatric care survivorship intervention in improving the overall health of older adults who have completed curative treatment for stage I-III breast cancer. Geriatric assessment is the complete examination of an elderly individual, which includes a full valuation of the physical and mental conditions, as well as a check of emotional state. Geriatric assessment and survivorship visits after treatment may reduce health burdens and improve the well-being and qual... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Register for Updates